Published in J Urol on August 01, 2001
Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol (2012) 1.13
Endoscopic ablation of Hunner's lesions in interstitial cystitis patients. Can Urol Assoc J (2009) 0.91
Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study. BMC Urol (2010) 0.77
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Mandatory second opinion surgical pathology at a large referral hospital. Cancer (1999) 3.40
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol (1998) 3.10
Telepathology diagnosis of prostrate needle biopsies. Hum Pathol (1997) 2.99
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol (2001) 2.68
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol (2000) 2.19
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol (2000) 2.05
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res (1996) 2.04
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol (1997) 1.97
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol (2001) 1.87
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol (1994) 1.87
Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol (1997) 1.86
Leiomyosarcoma of the paratesticular region: a clinicopathologic study. Am J Surg Pathol (2001) 1.84
Fungal sinusitis: diagnosis with CT and MR imaging. Radiology (1988) 1.82
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA (1997) 1.80
Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation. Hum Pathol (2001) 1.74
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol (1990) 1.65
Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol (1991) 1.63
Cystic lesions of the prostate gland. A sonographic--pathologic correlation. J Ultrasound Med (1990) 1.61
Consensus conference on second opinions in diagnostic anatomic pathology. Who, What, and When. Am J Clin Pathol (2000) 1.60
A case showing sclerosing adenosis and an unusual form of basal cell hyperplasia of the prostate. Am J Surg Pathol (1989) 1.59
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev (1998) 1.59
Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol (1991) 1.57
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
Gender differences in stage-adjusted bladder cancer survival. Urology (2000) 1.55
Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol (2001) 1.55
Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol (1996) 1.54
In situ adenocarcinoma of the bladder. Am J Surg Pathol (2001) 1.54
The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol (1995) 1.53
Metastatic prostatic carcinoma to supradiaphragmatic lymph nodes. A clinicopathologic and immunohistochemical study. Am J Surg Pathol (1987) 1.52
Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol (1994) 1.50
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Massive retroperitoneal angiomyolipoma. A lesion that may be confused with well-differentiated liposarcoma. Am J Clin Pathol (1989) 1.47
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology (1994) 1.45
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am (1993) 1.45
Molecular detection of primary bladder cancer by microsatellite analysis. Science (1996) 1.44
Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol (1993) 1.43
Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol (1989) 1.43
Can immunohistochemistry enhance the detection of micrometastases in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder? Am J Clin Pathol (1999) 1.42
Malignant rhabdoid tumor of the uterus. Int J Gynecol Pathol (1989) 1.42
Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol (1999) 1.39
Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. Am J Clin Pathol (1995) 1.39
Lipomeningioma: report of three cases and review of the literature. Neurosurgery (1989) 1.38
E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology (1999) 1.37
Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol (1997) 1.32
Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol (2001) 1.31
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol (1993) 1.28
Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A (1992) 1.28
Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol (1999) 1.27
Primary malignant melanoma of the urethra: a clinicopathologic analysis of 15 cases. Am J Surg Pathol (2000) 1.27
Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol (1992) 1.26
Tubulocystic clear cell adenocarcinoma arising within the prostate. Am J Surg Pathol (2000) 1.25
Granulomatous prostatitis on needle biopsy. Arch Pathol Lab Med (1997) 1.25
Granulomatous prostatitis: distinction among allergic, nonspecific, and post-transurethral resection lesions. Hum Pathol (1984) 1.24
ras gene mutations in human prostate cancer. Cancer Res (1990) 1.24
Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer (1991) 1.23
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate (1999) 1.20
Influence of radical prostatectomy on serum hormone levels. J Urol (1998) 1.19
Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer (1986) 1.19
Bioimpedance: novel use of a minimally invasive technique for cancer localization in the intact prostate. Prostate (1999) 1.19
Testicular vasculitis: implications for systemic disease. Hum Pathol (1988) 1.18
Genetic alterations in urinary bladder carcinosarcoma: evidence of a common clonal origin. Eur Urol (2000) 1.18
The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol (2000) 1.17
Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol (1998) 1.17
Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol (1994) 1.17
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology (2001) 1.16
Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res (1996) 1.16
Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol (1994) 1.15
Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. J Pathol (2007) 1.14
Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res (1997) 1.14
Factor VIII related antigen and glial fibrillary acidic protein immunoreactivity in the differential diagnosis of central nervous system hemangioblastomas. Am J Clin Pathol (1984) 1.13
Efficacy of restaining prostate needle biopsies with high-molecular weight cytokeratin. Hum Pathol (2000) 1.13
Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol (1986) 1.13
Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology (1999) 1.11
Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol (1996) 1.11
Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology (1999) 1.10
Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology (1999) 1.10
Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? J Urol (1999) 1.10
A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology (2000) 1.10